From: Subgroup identification for treatment selection in biomarker adaptive design
Scenario | A | B | C | D | E | F | G | H |
---|---|---|---|---|---|---|---|---|
Overall Test < 0.02 | 64 | 70 | 69 | 924 | 159 | 997 | 463 | 487 |
Comparison 2_DLDA | 26 | 35 | 33 | 483 | 153 | 503 | 455 | 481 |
ASD (1,1) | 33 | 34 | 32 | 822 | 115 | 951 | 436 | 455 |
ASD (1,2) | 20 | 25 | 25 | 682 | 116 | 859 | 451 | 476 |
ASD (2,1) | 24 | 33 | 33 | 587 | 146 | 665 | 350 | 392 |
ASD (2,2) | 23 | 33 | 31 | 488 | 153 | 411 | 286 | 352 |
Overall Test > 0.02 | 936 | 930 | 931 | 76 | 841 | 3 | 537 | 513 |
Comparison 2_DLDA | 319 | 355 | 401 | 24 | 771 | 2 | 510 | 488 |
ASD (1,1) | 130 | 131 | 115 | 11 | 298 | 0 | 388 | 361 |
ASD (1,2) | 247 | 266 | 308 | 18 | 676 | 2 | 492 | 475 |
ASD (2,1) | 216 | 260 | 280 | 20 | 709 | 2 | 226 | 237 |
ASD (2,2) | 174 | 219 | 255 | 23 | 717 | 1 | 142 | 160 |
Overall power_DLDA | 383 | 425 | 470 | 948 | 930 | 999 | 973 | 975 |
ASD (1,1) | 194 | 201 | 184 | 935 | 457 | 997 | 851 | 848 |
ASD (1,2) | 311 | 336 | 377 | 942 | 835 | 999 | 955 | 962 |
ASD (2,1) | 280 | 330 | 349 | 944 | 868 | 999 | 689 | 724 |
ASD (2,2) | 238 | 289 | 324 | 947 | 876 | 998 | 605 | 647 |